Bicycle Therapeutics Plc ADR (BCYC)

$6.99 +0.05 (0.72%)
Market Cap 481.41M
Revenue (ttm) 35.28M
Net Income (ttm) -169.03M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -479.11%
Debt to Equity Ratio 0.00
Volume 96,400
Avg Vol 311,632
Day's Range N/A - N/A
Shares Out 69.37M
Stochastic %K 32%
Beta 1.47
Analysts Strong Sell
Price Target $20.91

Company Profile

Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase I/II/III clinical trials for the treatment of high nectin-4 expressing tumors; BT5528 (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing t...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 1223 261 503
Address:
Portway Building, Blocks A & B Granta Park Great Abington, Cambridge, United Kingdom
SQUEAKSBANDIT
SQUEAKSBANDIT Dec. 18 at 1:34 AM
$BCYC anyone think we start getting some good news in jan? barely moved while some other names exploded on the radiopharm hype
2 · Reply
dgbio
dgbio Dec. 16 at 11:57 AM
$BCYC This is important. Pb-212 is an indirect (via Bi-212 and Po-212) source of alpha-particles. Alpha-based radiopharmaceuticals are expected to be much safer. https://investors.bicycletherapeutics.com/news-releases/news-release-details/bicycle-therapeutics-establishes-multiple-strategic-partnerships
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 10 at 3:57 PM
$BCYC Share Price: $7.37 Contract Selected: Jun 18, 2026 $5 Calls Buy Zone: $0.42 – $0.53 Target Zone: $0.70 – $0.85 Potential Upside: 55% ROI Time to Expiration: 189 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
JarvisFlow
JarvisFlow Nov. 24 at 5:55 PM
Truist Securities has updated their rating for Bicycle Therapeutics ( $BCYC ) to Hold with a price target of 10.
0 · Reply
LabPsycho
LabPsycho Nov. 20 at 9:27 PM
$BCYC Moving towards predicted target.
1 · Reply
eladfff
eladfff Nov. 14 at 4:19 AM
$BCYC Being investigated for fraud. What happens when you fail to do any of the things you told shareholders you were going to do in 2H25 https://www.accessnewswire.com/newsroom/en/business-and-professional-services/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-1100499
4 · Reply
RadioIsotope25
RadioIsotope25 Nov. 12 at 11:28 PM
$RADX TRP Target Selection & Drug Design Summit 2026 (February 24–26, Boston, MA) - Over three days, experts from Novartis, Bayer, Abdera, Radiopharm Theranostics, AstraZeneca, OncoOne, PentixaPharm, Bicycle Therapeutics, Université Laval $BAYRY $NVS $BCYC $AZN
0 · Reply
LabPsycho
LabPsycho Nov. 9 at 8:03 PM
$BCYC @eladfff Good post. That is in part why I think this is in the $5's before EOY.
1 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Nov. 5 at 9:52 PM
$BCYC
0 · Reply
eladfff
eladfff Nov. 5 at 7:56 PM
$BCYC Failed to deliver multiple datasets on time. Were supposed to update Duravelo-1 data in 2H25 and didn't; were supposed to have BT5528 Ph1 data in 2H25 and don't; were supposed to have dose selection and interim topline data for Duravelo-2 in 4Q25 and don't have it. Failed to deliver any of the datasets mgmt said they would in the second half of this year. Market has no use for that and it's showing.
1 · Reply
Latest News on BCYC
Bicycle Therapeutics Establishes Multiple Strategic Partnerships to Create End-to-End Supply Chain to Support its Wholly Owned Radiopharmaceutical Pipeline

Dec 16, 2025, 1:00 AM EST - 9 days ago

Bicycle Therapeutics Establishes Multiple Strategic Partnerships to Create End-to-End Supply Chain to Support its Wholly Owned Radiopharmaceutical Pipeline

Bicycle Therapeutics to Participate in the Jefferies London Healthcare Conference

Nov 12, 2025, 4:05 PM EST - 6 weeks ago

Bicycle Therapeutics to Participate in the Jefferies London Healthcare Conference

Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results

Oct 30, 2025, 7:00 AM EDT - 2 months ago

Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results

Bicycle Therapeutics: Looking For Their Niche, Addressing Cash Burn

Oct 15, 2025, 8:36 AM EDT - 2 months ago

Bicycle Therapeutics: Looking For Their Niche, Addressing Cash Burn

Bicycle Therapeutics Plc (BCYC) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 12:06 PM EDT - 3 months ago

Bicycle Therapeutics Plc (BCYC) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Bicycle Therapeutics Strengthens Board of Directors with New Appointments

Sep 8, 2025, 4:05 PM EDT - 3 months ago

Bicycle Therapeutics Strengthens Board of Directors with New Appointments

Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results

Aug 8, 2025, 7:00 AM EDT - 4 months ago

Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results

Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 2, 2025, 4:05 PM EDT - 6 months ago

Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Bicycle Therapeutics Announces Poster Presentations at the 2025 ASCO Annual Meeting

May 22, 2025, 5:05 PM EDT - 7 months ago

Bicycle Therapeutics Announces Poster Presentations at the 2025 ASCO Annual Meeting

Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results

May 1, 2025, 7:00 AM EDT - 8 months ago

Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results

Bicycle Therapeutics Announces Presentation of Additional Human Radiopharmaceutical Imaging Data for MT1-MMP at the American Association for Cancer Research Annual Meeting 2025

Apr 29, 2025, 7:00 AM EDT - 8 months ago

Bicycle Therapeutics Announces Presentation of Additional Human Radiopharmaceutical Imaging Data for MT1-MMP at the American Association for Cancer Research Annual Meeting 2025

Bicycle Therapeutics: Maybe Underwhelming, But I Don't Think They Should Be This Discounted

Apr 22, 2025, 3:47 AM EDT - 8 months ago

Bicycle Therapeutics: Maybe Underwhelming, But I Don't Think They Should Be This Discounted

Bicycle Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Apr 1, 2025, 7:00 AM EDT - 9 months ago

Bicycle Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Bicycle Therapeutics Announces New Board and Key Clinical Leadership Appointments

Mar 27, 2025, 7:00 AM EDT - 9 months ago

Bicycle Therapeutics Announces New Board and Key Clinical Leadership Appointments

Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results

Feb 25, 2025, 7:00 AM EST - 10 months ago

Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results

Bicycle Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 5, 2025, 7:00 AM EST - 11 months ago

Bicycle Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Bicycle Therapeutics: Trading At Cash, Underwhelming But Not Unsalvageable Data

Feb 2, 2025, 5:26 AM EST - 11 months ago

Bicycle Therapeutics: Trading At Cash, Underwhelming But Not Unsalvageable Data

Bicycle Therapeutics Announces Updated Topline Zelenectide Pevedotin Data and Highlights 2025 Strategic Priorities and Milestones

Jan 13, 2025, 7:00 AM EST - 1 year ago

Bicycle Therapeutics Announces Updated Topline Zelenectide Pevedotin Data and Highlights 2025 Strategic Priorities and Milestones

Bicycle Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Jan 9, 2025, 7:00 AM EST - 1 year ago

Bicycle Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene Amplification

Dec 12, 2024, 6:30 PM EST - 1 year ago

Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene Amplification

Bicycle Therapeutics Expands Clinical Advisory Board with Three Distinguished Global Oncology Experts

Dec 10, 2024, 7:00 AM EST - 1 year ago

Bicycle Therapeutics Expands Clinical Advisory Board with Three Distinguished Global Oncology Experts

Bicycle Therapeutics to Present Data for Zelenectide Pevedotin at 2024 San Antonio Breast Cancer Symposium and Provide Program Update

Nov 25, 2024, 5:30 PM EST - 1 year ago

Bicycle Therapeutics to Present Data for Zelenectide Pevedotin at 2024 San Antonio Breast Cancer Symposium and Provide Program Update

Bicycle Therapeutics: Looking Again At An Intriguing Developmental Concern

Nov 7, 2024, 10:04 AM EST - 1 year ago

Bicycle Therapeutics: Looking Again At An Intriguing Developmental Concern

Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results

Oct 31, 2024, 7:00 AM EDT - 1 year ago

Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results

Bicycle Therapeutics Announces First Human Imaging Data from European Association of Nuclear Medicine 2024 Congress and Outlines Strategy for Leadership in Next-Generation Radiopharmaceuticals

Oct 23, 2024, 7:00 AM EDT - 1 year ago

Bicycle Therapeutics Announces First Human Imaging Data from European Association of Nuclear Medicine 2024 Congress and Outlines Strategy for Leadership in Next-Generation Radiopharmaceuticals

Bicycle Therapeutics to Present Radiopharmaceuticals Data at European Association of Nuclear Medicine 2024 Congress

Oct 16, 2024, 7:00 AM EDT - 1 year ago

Bicycle Therapeutics to Present Radiopharmaceuticals Data at European Association of Nuclear Medicine 2024 Congress

Bicycle Therapeutics Presents Updated Clinical Results Across Oncology Pipeline at ESMO Congress 2024

Sep 14, 2024, 3:00 AM EDT - 1 year ago

Bicycle Therapeutics Presents Updated Clinical Results Across Oncology Pipeline at ESMO Congress 2024

Bicycle Therapeutics' Lead Cancer Candidate's Has High-Opportunity, Analyst Initiates With Bullish Tone

Sep 6, 2024, 1:37 PM EDT - 1 year ago

Bicycle Therapeutics' Lead Cancer Candidate's Has High-Opportunity, Analyst Initiates With Bullish Tone

Bicycle Therapeutics to Participate in Upcoming Investor Conferences

Aug 21, 2024, 7:00 AM EDT - 1 year ago

Bicycle Therapeutics to Participate in Upcoming Investor Conferences

Bicycle Therapeutics Is Looking Increasingly Attractive

Aug 20, 2024, 7:37 AM EDT - 1 year ago

Bicycle Therapeutics Is Looking Increasingly Attractive

Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results

Aug 6, 2024, 7:05 AM EDT - 1 year ago

Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results

25 Snack Food Suppliers Queue Up for ReposiTrak's Rapidly Expanding Food Traceability Network

Aug 6, 2024, 7:00 AM EDT - 1 year ago

25 Snack Food Suppliers Queue Up for ReposiTrak's Rapidly Expanding Food Traceability Network

BSY MASS MLI NJR OFIX QBTS SMMT

Bicycle Therapeutics Announces Four Abstracts Accepted for Presentation at the ESMO Congress 2024

Jul 22, 2024, 7:00 AM EDT - 1 year ago

Bicycle Therapeutics Announces Four Abstracts Accepted for Presentation at the ESMO Congress 2024

Bicycle Therapeutics to Present Pharmacokinetic and Safety Evaluation of Lead BTC® Molecules in Phase 1/2 Trials at the 2024 ASCO Annual Meeting

May 23, 2024, 5:05 PM EDT - 1 year ago

Bicycle Therapeutics to Present Pharmacokinetic and Safety Evaluation of Lead BTC® Molecules in Phase 1/2 Trials at the 2024 ASCO Annual Meeting

Bicycle Therapeutics Announces $555 Million Private Placement Equity Financing

May 23, 2024, 7:00 AM EDT - 1 year ago

Bicycle Therapeutics Announces $555 Million Private Placement Equity Financing

Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results

May 2, 2024, 7:00 AM EDT - 1 year ago

Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results

Bicycle Therapeutics Announces Two Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting

Apr 24, 2024, 10:05 AM EDT - 1 year ago

Bicycle Therapeutics Announces Two Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting

Bicycle Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Apr 2, 2024, 7:00 AM EDT - 1 year ago

Bicycle Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference

2 More Potential Biotech Buyout Targets

Mar 25, 2024, 1:07 PM EDT - 1 year ago

2 More Potential Biotech Buyout Targets

AZN BMY EXEL LLY MRK NVS TAK

Bicycle: 2nd Half Of 2024 Data Could Provide Significant Inflection Point

Mar 12, 2024, 12:09 PM EDT - 1 year ago

Bicycle: 2nd Half Of 2024 Data Could Provide Significant Inflection Point

Bicycle Therapeutics to Present at the AACR Annual Meeting 2024

Mar 5, 2024, 4:35 PM EST - 1 year ago

Bicycle Therapeutics to Present at the AACR Annual Meeting 2024

Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results

Feb 20, 2024, 7:05 AM EST - 2 years ago

Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results

Bicycle Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 7, 2024, 7:00 AM EST - 2 years ago

Bicycle Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Bicycle Therapeutics Provides Data Updates for Three Clinical Programs and Strategy Overview at First R&D Day

Dec 14, 2023, 7:00 AM EST - 2 years ago

Bicycle Therapeutics Provides Data Updates for Three Clinical Programs and Strategy Overview at First R&D Day

Bicycle Therapeutics to Host R&D Day on December 14

Nov 30, 2023, 7:00 AM EST - 2 years ago

Bicycle Therapeutics to Host R&D Day on December 14

Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results and Announces Upcoming R&D Day

Nov 2, 2023, 7:00 AM EDT - 2 years ago

Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results and Announces Upcoming R&D Day

Bicycle Therapeutics Selected to Participate in FDA Program to Expedite Commercial Manufacturing Readiness of BT8009 for Metastatic Bladder Cancer

Oct 19, 2023, 7:00 AM EDT - 2 years ago

Bicycle Therapeutics Selected to Participate in FDA Program to Expedite Commercial Manufacturing Readiness of BT8009 for Metastatic Bladder Cancer

Macomics Announces the Appointment of Kevin Lee as Independent Non-Executive Director

Oct 19, 2023, 4:00 AM EDT - 2 years ago

Macomics Announces the Appointment of Kevin Lee as Independent Non-Executive Director

SQUEAKSBANDIT
SQUEAKSBANDIT Dec. 18 at 1:34 AM
$BCYC anyone think we start getting some good news in jan? barely moved while some other names exploded on the radiopharm hype
2 · Reply
dgbio
dgbio Dec. 16 at 11:57 AM
$BCYC This is important. Pb-212 is an indirect (via Bi-212 and Po-212) source of alpha-particles. Alpha-based radiopharmaceuticals are expected to be much safer. https://investors.bicycletherapeutics.com/news-releases/news-release-details/bicycle-therapeutics-establishes-multiple-strategic-partnerships
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 10 at 3:57 PM
$BCYC Share Price: $7.37 Contract Selected: Jun 18, 2026 $5 Calls Buy Zone: $0.42 – $0.53 Target Zone: $0.70 – $0.85 Potential Upside: 55% ROI Time to Expiration: 189 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
JarvisFlow
JarvisFlow Nov. 24 at 5:55 PM
Truist Securities has updated their rating for Bicycle Therapeutics ( $BCYC ) to Hold with a price target of 10.
0 · Reply
LabPsycho
LabPsycho Nov. 20 at 9:27 PM
$BCYC Moving towards predicted target.
1 · Reply
eladfff
eladfff Nov. 14 at 4:19 AM
$BCYC Being investigated for fraud. What happens when you fail to do any of the things you told shareholders you were going to do in 2H25 https://www.accessnewswire.com/newsroom/en/business-and-professional-services/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-1100499
4 · Reply
RadioIsotope25
RadioIsotope25 Nov. 12 at 11:28 PM
$RADX TRP Target Selection & Drug Design Summit 2026 (February 24–26, Boston, MA) - Over three days, experts from Novartis, Bayer, Abdera, Radiopharm Theranostics, AstraZeneca, OncoOne, PentixaPharm, Bicycle Therapeutics, Université Laval $BAYRY $NVS $BCYC $AZN
0 · Reply
LabPsycho
LabPsycho Nov. 9 at 8:03 PM
$BCYC @eladfff Good post. That is in part why I think this is in the $5's before EOY.
1 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Nov. 5 at 9:52 PM
$BCYC
0 · Reply
eladfff
eladfff Nov. 5 at 7:56 PM
$BCYC Failed to deliver multiple datasets on time. Were supposed to update Duravelo-1 data in 2H25 and didn't; were supposed to have BT5528 Ph1 data in 2H25 and don't; were supposed to have dose selection and interim topline data for Duravelo-2 in 4Q25 and don't have it. Failed to deliver any of the datasets mgmt said they would in the second half of this year. Market has no use for that and it's showing.
1 · Reply
eladfff
eladfff Nov. 5 at 7:42 PM
$BCYC gnarly weekly candle. Down 30% in the last 4 sessions !
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 5 at 3:49 PM
$BCD $BCH $BCO $BCS $BCYC 🔥
0 · Reply
bigtuna7
bigtuna7 Nov. 5 at 2:47 PM
$BCYC Cmon
2 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Nov. 5 at 5:59 AM
$BCYC wow this name got more affordable and fast uou guys adding waiting selling ?
1 · Reply
Strangperson
Strangperson Nov. 4 at 4:42 PM
$BCYC ouch
0 · Reply
dgbio
dgbio Nov. 1 at 2:27 AM
$BCYC Considering all the changes at the FDA, one quarter delay is nothing. Padcev is growing but this is the reason only to value Bicycle more. And other competitors: Corbus' drug has weaker safety (though somewhat better than Padcev), all others are behind doing p1. If zele gets approved it's going to be a huge win and if Bicycle needs another quarter to set the pivotal trial right it's entirely ok. May not be even a quarter, just an extra month pushing it to 2026.
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Oct. 31 at 8:50 PM
$BCYC
0 · Reply
notreload_ai
notreload_ai Oct. 31 at 2:04 PM
RBC Capital analyst lowered the rating for $BCYC after the Q3 report, citing delays in key drug development programs like zelenectide and BT5528. https://notreload.xyz/bicycle-therapeutics-downgrade-pipeline-delay-analysis/
0 · Reply
topstockalerts
topstockalerts Oct. 30 at 6:16 PM
$BCYC here it comes… 🚨
0 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Oct. 30 at 5:33 PM
$BCYC show of hands who flipped on the pop? who is taking the round trip?
1 · Reply
CrispDry
CrispDry Oct. 30 at 5:25 PM
$BCYC why the spike?
1 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Oct. 30 at 3:03 PM
$BCYC data delayed till q1 while getting regulatory feedback anyone have a take ?
1 · Reply